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White matter alterations in Alzheimer’s disease without concomitant pathologies
Aims: Most individuals with AD neuropathological
changes have co-morbidities which have an impact on
the integrity of the WM. This study analyses oligoden-
drocyte and myelin markers in the frontal WM in a
series of AD cases without clinical or pathological co-
morbidities. Methods: From a consecutive autopsy ser-
ies, 206 cases had neuropathological changes of AD;
among them, only 33 were AD without co-morbidities.
WM alterations were first evaluated in coronal sections
of the frontal lobe in every case. Then, RT-qPCR and
immunohistochemistry were carried out in the frontal
WM of AD cases without co-morbidities to analyse the
expression of selected oligodendrocyte and myelin
markers. Results: WM demyelination was more marked
in AD with co-morbidities when compared with AD
cases without co-morbidities. Regarding the later,
mRNA expression levels of MBP, PLP1, CNP, MAG,
MAL, MOG and MOBP were preserved at stages I–II/0–
A when compared with middle-aged (MA) individuals,
but significantly decreased at stages III–IV/0–C. This
was accompanied by reduced expression of NG2 and
PDGFRA mRNA, reduced numbers of NG2-, Olig2- and
HDAC2-immunoreactive cells and reduced glucose
transporter immunoreactivity. Partial recovery of some
of these markers occurred at stages V–VI/B–C. Conclu-
sions: The present observations demonstrate that co-
morbidities have an impact on WM integrity in the
elderly and in AD, and that early alterations in oligo-
dendrocytes and transcription of genes linked to myelin
proteins in WM occur in AD cases without co-morbidi-
ties. These are followed by partial recovery attempts at
advanced stages. These observations suggest that oligo-
dendrocytopathy is part of AD.
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Introduction
Reduced white matter (WM) volume, WM lesions and
altered WM integrity and cortical disconnection occur
in the ageing human brain [1-10]. Age-related WM
decay is associated with memory impairment and
symptoms of depression in an anatomically specific
manner [1-14]. Reduced myelin basic protein (MBP)
and 2’,3’-cyclic nucleotide 3’ phosphodiesterase (CNP)
levels [15], and alterations in the number of oligoden-
drocytes and oligodendroglial precursor cells (OPCs/
NG2-positive cells), have been reported in aged pri-
mates and rodents [16].
Reduced WM size, WM hyper-lucencies and myelin
and axon damage are common in sporadic Alzheimer’s
disease (AD), as revealed by neuroimaging methods,
mainly magnetic resonance imaging (MRI), and
*Correspondence: Isidro Ferrer, Department of Pathology and
Experimental Therapeutics, University of Barcelona, Feixa Llarga
sn, 08907 Barcelona, Spain. Tel: 34 94 4035808; Fax: 34 93
4035808; E-mail: 8082ifa@gmail.com
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
654
Neuropathology and Applied Neurobiology (2020), 46, 654–672 doi: 10.1111/nan.12618
particularly diffusion tensor imaging (DTI) and func-
tional MRI (fMRI) [3-4,12,14,17-22]. Patients with
moderate cognitive impairment (MCI) of AD-type exhi-
bit alteration of the WM integrity which further deteri-
orates with disease progression [5,23-27]. WM
alterations appear before the appearance of clinical
symptoms [28]. Atrophy of WM, decreased myelin den-
sity and demyelination and predominant WM vulnera-
bility of the frontal and parietal lobes are also observed
in post mortem neuropathological studies [2,29-32].
Myelin loss mainly involves areas that are myelinated
late in the development [8,33,34]. Breakdown of WM
integrity is considered a principal component of AD,
contributing to neural disconnection and progression of
clinical symptoms and dementia [13].
However, most studies of WM in the human ageing
brain have not considered that in the elderly, most
individuals have AD pathology that cannot be visual-
ized with current neuroimaging methods. Therefore, we
cannot be certain that a reasonable percentage of aged
individuals subjected to neuroimaging studies suffer
concomitant AD pathology. Moreover, the presence of
a certain number of b-amyloid plaques and neurofibril-
lary tangles (NFTs) in the elderly have been considered
until recently to be normal brain ageing; these cases
might have been classified at post mortem as normal
aged individuals.
Furthermore, co-morbidities are common in the age-
ing brain and in AD. Vascular cognitive impairment
and dementia are prevalent in old age [35-42]. The
combination of AD and cerebrovascular disease is very
common [43-49]. Other clinical co-morbidities include
arterial hypertension (HTA), type II diabetes, cardiac,
hepatic and renal failure and respiratory insufficiency;
pathological co-morbidities include neurodegenerative
disorders with abnormal protein aggregates such as
other tauopathies, Lewy body diseases and TDP-43 pro-
teinopathies, among others and hippocampal sclerosis
[50-56].
This study was designed to analyse molecular alter-
ations in the WM linked to oligodendrocytes and mye-
lin in cases with AD pathological changes without
clinical or pathological co-morbidities. These cases were
first selected from a consecutive series of autopsies in a
general hospital in which AD was one of the post mor-
tem neuropathological diagnoses. Cases with clinical
and pathological co-morbidities were not included in
the second part of the study.
In the second part of the study, gene transcription
was assessed with targeted RT-qPCR, and protein
expression of altered genes by immunohistochemistry in
the WM of the centrum semi-ovale of the frontal lobe in
cases with AD pathology without clinical and pathologi-
cal co-morbidities at different Braak stages of disease
progression. Selected genes for analysis included mark-
ers of the oligodendrocyte lineage, genes encoding struc-
tural proteins of myelin and genes involved in energy
metabolism and axon maintenance. Adult NG2-glia
have the capacity to produce myelinating oligodendro-
cytes [57,58] thus contributing to oligodendrocyte and
myelin turnover and regeneration in the adult CNS
[59]. Stages of oligodendrocyte lineage are identified by
the expression of platelet-derived growth factor receptor
a polypeptide (PDGF-Ra), SRY-Box-10 (Sox10), NK2
homeobox 2 (Nkx2.2), oligodendrocyte transcription
factor 1 (Olig1) and oligodendrocyte lineage transcrip-
tion factor 2 (Olig2), among others [60]. After oligoden-
drocyte differentiation, myelination is triggered by
myelin regulatory factor (MYRF) which is expressed in
postmitotic oligodendrocytes [61]. Myelination is linked
to increased expression of myelin basic protein (MBP),
myelin-associated glycoprotein (MAG), proteolipid pro-
tein 1 (PLP1), myelin oligodendrocyte glycoprotein
(MOG) and 20, 30-cyclic nucleotide 30 phosphodiesterase
(CNP), among others [62-68]. Finally, blood-derived
glucose is taken up by oligodendrocytes through glucose
transporter 1 (GLUT1) encoded by SLC2A1. Glucose is
metabolized via glycolysis to produce pyruvate and lac-
tate which are delivered to the axons through specific
solute carriers, the monocarboxylate transporters (MCT)
located in cell membranes [69,70]. MCT1 is mainly
expressed in oligodendrocytes [71,72]. Thus, both
GLUT1 and MCT1 produced in oligodendrocytes are
involved in axon maintenance independently of the
complementary myelin/axon trophic alliance. These
markers were analysed in this study.
Finally, histone deacetylases (HDACs) remove specific
acetyl groups on a histone enabling it to interact with
DNA thereby modulating gene transcription. HDAC1
and HDAC2 are expressed in oligodendrocytes [73,74].
HDAC1 immunoreactivity was also assessed in the
nuclei of glial cells in the WM.
Our aim was to discern which alterations in the WM
in the general population affected by AD pathological
changes were linked to AD and not to concomitant
clinical and pathological co-morbidities.
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Material and methods
Selection of samples
First series Cases for study were obtained at the
Bellvitge University Hospital following the guidelines of
the Spanish legislation (Real Decreto 1716/2011) and
the approval of the local ethics committee. Clinical
parameters were retrieved after the revision of the
complete clinical history in every case. Only cases with
comprehensive clinical information were separated for
further analysis. The first series of cases was chosen
from consecutive autopsies carried out from 2009 to
2015. The current protocol for the autopsies in adult
donors was as follows: one hemisphere was
immediately cut in coronal sections, 1 cm thick and
selected areas of the encephalon were rapidly dissected,
frozen on metal plates over dry-ice, placed in individual
air-tight plastic bags and stored at 80°C until use for
biochemical studies. The other hemisphere was fixed by
immersion in 4% buffered formalin for 3 weeks for
morphological studies. For the current
neuropathological study, 4-µm-thick sections from 20
representative brain regions were stained with
haematoxylin and eosin, periodic acid-Schiff (PAS) and
Kl€uver–Barrera, or processed for
immunohistochemistry for microglia Iba1, glial
fibrillary acidic protein (GFAP), b-amyloid, phospho-tau
(clone AT8), a-synuclein, TDP-43 and ubiquitin, using
EnVision + System peroxidase (Dako), and
diaminobenzidine and H2O2. In addition, 1-cm-thick
coronal sections of the frontal lobe at the level of the
head of the caudate and putamen were obtained in
every case. Blocks were embedded in paraffin, cut at a
thickness of 7 µm, de-waxed and stained with
haematoxylin and eosin, and with Kl€uver–Barrera.
Details of the 20 selected regions and the
methodological protocols for current neuropathological
studies are described elsewhere [75]. From among
autopsies following this procedure, including the
availability of appropriate clinical information and
suitability of white matter sections stained with
Kl€uver–Barrera for densitometric studies, 470 of 713
autopsies were initially selected. Three groups were
defined. First, all cases with NFT pathology and/or with
cerebral b-amyloid deposition, covering NFT pathology
stages I–VI of Braak and b-amyloid deposition in the
form of diffuse and/or neuritic plaques Braak stages 0
(no deposits) to C [76], were chosen for further
classification. These were 128 men and 78 women
(total n = 206); mean age (SEM): 73.3  9.6 years.
AD cases were categorized as ADI–II/0-A (n = 113,
men: 83, women: 30; age: 69.1  8.9 years); ADIII–
IV/0–C (n = 70, men: 36, women: 34; age:
78.4  7.6 years) and ADV–VI/B–C (n = 23, men: 9,
women: 14; age: 78.5  8.5 years). Most of these
cases encompassed a diversity of co-morbidities
including metabolic disorders such as HTA, type II
diabetes, hyperlipaemia, renal or liver failure and
chronic respiratory failure; peripheral and central
vascular pathology; age-related neurodegenerative
diseases, such as other tauopathies, Lewy body
pathology and TDP-43 proteinopathy, among others;
hippocampal sclerosis and long agonic state, or
vegetative state. Regarding cerebrovascular pathology,
cases with cerebral infarcts, including micro-infarcts,
lacunes, infarcts in the watershed areas, vascular
leucoencephalopathy, hippocampal sclerosis and status
cribosus; and cases with severe atherosclerosis,
moderate or severe artheriolosclerosis, hypertensive
angiopathy, inflammatory vascular diseases and
vascular malformations were considered as AD with
vascular co-morbidity. This group was classified as AD
with concomitant pathology, AD-Co, and was made up
of 173 cases, categorized as ADI–II/0–A (n = 104),
ADIII–IV/0–C (n = 63) and ADV–VI/B–C (n = 7).
Only 33 of the 206 were classified as cases with AD
without co-morbidities. Cases with concomitant mild
small blood vessel disease were included in this series.
This group was made up of by 15 men and 18 women;
age: 76.3  8.6 years. AD cases without co-morbidities
were categorized as follows: ADI–II/0–A (n = 9, men:
5, women: 4; age: 68.5  11.3 years); ADIII–IV/0–C
(n = 8, men: 2, women: 6; age: 77.7  4.8 years);
ADV–VI/B–C (n = 16, men: 8, women: 8; age:
80.7  5.6 years). All these cases were sporadic; famil-
ial AD was not included in this study.
The third group (n = 20) was made up of young
cases (middle-aged: MA) chosen at random among the
remaining 264 cases (470 minus 206). This group
consisted of 10 men and 10 women; age:
48.1  7.7 years. MA did not have the clinical risk
factors and co-morbidities mentioned in previous para-
graphs; they did not have neurological or mental
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diseases, and the neuropathological study did not show
abnormalities. The control group must be not inter-
preted as an age-matched control group, but as a con-
trol group of normal WM in MA individuals.
Second series Only cases with AD pathology without
co-morbidities were the focus of this part of the study.
These cases were the same as those of the second
group of the first series. In addition, 10 MA cases (6
men, 4 women; age: 51.7  4.7 years) from the third
group of the first series were included and processed in
parallel. The total number of MA and AD cases in this
series is detailed in Table 1. All these cases were used
for specific immunohistochemical studies. However,
frozen samples were available for 24 AD cases and 10
controls. In these cases, the brain pH at the time of the
autopsy was between 6.2 and 6.4, and the RNA
integrity number (RIN) higher than 6 (excepting one
case). AD cases at stages I–II/0-A had no neurological
symptoms; AD cases at stages III–IV/0–C had no
neurological symptoms nor were they affected by mild
cognitive impairment; AD cases at stages V–VI/B–C
had severe cognitive impairment or dementia.
Quantitative densitometric studies of the WM
stained with Kl€uver–Barrera
Photomicrographs of the centrum semi-ovale of Kl€uver–
Barrera-stained sections, at the level of the head of the
caudate and putamen as described above, were obtained
at a mid-distance between the inferior frontal sulcus
and the cingulate sulcus, approximately at 0.7–1 cm
from the external vertex of the lateral ventricle. Figures
were obtained at a magnification of 9 200, covering an
area of 0.126 mm2, using a DP25 camera adapted to
an Olympus BX50 light microscope. The pictures, two
areas per case in every case, were analysed using Photo-
shop software. The density of myelin was calculated as
the intensity of blue normalized for the total area and
expressed as arbitrary units per area. The normality of
distribution was analysed with the Kolmogorov–Smir-
nov test. Results were analysed with one-way ANOVA and
post hoc Tukey. Differences between MA and the two
groups of AD, and between the different stages in pure
AD cases, were considered statistically significant at
*P < 0.05, **P < 0.01, ***P < 0.001 when comparing
MA with AD and AD-Co, and ##P < 0.01 when com-
paring AD-Co with ‘pure’ AD.
RNA purification and RT-qPCR
The WM was dissected from the grey matter in 34
cases, corresponding to 9 ADI–II/0–A, 8 ADIII–IV/0–C,
7 ADV–VI/B–C and 10 MA. WM samples at different
AD stages and MA cases were processed in parallel.
RNA from frozen WM was extracted following the
instructions of the supplier (RNeasy Mini Kit, Qiagen
GmbH, Hilden, Germany). RNA integrity and 28S/18S
Table 1. Summary of cases of AD without concomitant co-mor-
bidities and pathologies
Case ID Diagnosis Sex Age PM delay RIN WM
1 AD I/0 M 56 07 h 10 min 7.80
2 AD I/A W 74 02 h 45 min 7.70
3 AD I/A W 57 05 h 00 min 6.50
4 AD I/A M 66 09 h 45 min 6.30
5 AD II/0 M 67 07 h 15 min 6.90
6 AD II/0 M 57 04 h 30 min 7.10
7 AD II/A W 88 08 h 00 min 6.90
8 AD II/A M 66 04 h 55 min 7.50
9 AD II/A W 86 02 h 15 min 8.30
10 AD III/0 M 81 01 h 30 min 7.60
11 AD III/0 M 66 05 h 45 min 7.50
12 AD III/0 W 79 03 h 35 min 7.40
13 AD III/A W 82 02 h 00 min 7.20
14 AD III/A W 77 03 h 10 min 6.40
15 AD III/B W 76 03 h 50 min 7.20
16 AD IV/A W 80 02 h 45 min 5.40
17 AD IV/C W 81 05 h 00 min 7.30
18 AD V/B W 74 05 h 30 min 7.70
19 AD V/B M 86 04 h 15 min 7.90
20 AD V/B M 73 04 h 30 min 6.90
21 AD V/B W 82 01 h 45 min –
22 AD V/B M 75 11 h 30 min –
23 AD VI/C W 72 09 h 30 min 6.40
24 AD VI/C W 85 16 h 15 min 8.20
25 AD V/C M 85 03 h 45 min 7.80
26 AD V/C M 77 16 h 00 min 7.10
27 AD VI/C W 82 10 h 00 min –
28 AD V/C W 86 10 h 00 min –
29 AD V/C W 85 12 h 10 min –
30 AD V/C M 77 08 h 00 min –
31 AD V/C M 79 07 h 30 min –
32 AD V/C M 93 03 h 00 min –
33 AD VI/C W 81 05 h 15 min –
34 MA W 62 11 h 00 min 8.40
35 MA W 53 03 h 00 min 7.70
36 MA M 55 05 h 40 min 8.30
37 MA M 39 09 h 15 min 7.10
38 MA W 46 14 h 05 min 7.20
39 MA W 66 04 h 15 min 7.80
40 MA M 57 03 h 00 min 8.20
41 MA M 50 17 h 15 min 8.00
42 MA W 54 06 h 45 min 7.20
43 MA M 35 17 h 00 min 6.80
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ratios were determined with the Agilent Bioanalyzer
(Agilent Technologies Inc, Santa Clara, CA, USA). RIN
values are shown in Table 1. Samples were treated
with DNase digestion, and RNA concentration was
evaluated using a NanoDropTM Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA).
TaqMan RT-qPCR assays were performed in dupli-
cate for each gene on cDNA samples in 384-well opti-
cal plates using an ABI Prism 7900 Sequence
Detection system (Applied Biosystems, Life Technolo-
gies, Waltham, MA, USA). For each 10 ll TaqMan
reaction, 4.5 ll cDNA was mixed with 0.5 ll 20 9
TaqMan Gene Expression Assays and 5 ll of 2 9 Taq-
Man Universal PCR Master Mix (Applied Biosystems).
TaqMan probes used in the study are detailed in
Table 2. Values of GUS-b were used as internal con-
trols for normalization [77]. The parameters of the
reactions were 50°C for 2 min, 95°C for 10 min and
40 cycles of 95°C for 15 s and 60°C for 1 min. Finally,
capture of all TaqMan PCR data was made using the
Sequence Detection Software (SDS version 2.2.2,
Applied Biosystems). For the data analysis, threshold
cycle (CT) values for each sample were processed to
obtain the double delta CT (DDCT) values. First, delta
CT (DCT) values were calculated as the normalized CT
values for each target gene in relation to the CT of
endogenous controls GUS-b. Then, DDCT values were
obtained from the DCT of each sample minus the mean
DCT of the population of control samples.
The normality of distribution of fold-change values
was analysed with the Kolmogorov–Smirnov test. Pear-
son’s correlation coefficient was used to assess a possi-
ble linear association between two continuous
quantitative variables. To determine the relationship
between gene expression and RIN values according to
pathologic variables, we used the analysis of covariance
(ANCOVA) in the 16 probes. Statistical analysis of the
expression data between groups was made using one-
way analysis of variance (ANOVA) followed by Tukey
posttest, or Kruskal–Wallis test followed by Dunn’s post
hoc test when required using the SPSS software (IBM
Corp. Released 2013. IBM SPSS Statistics for Windows,
Version 21.0; Armonk, NY: IBM Corp). Outliers were
detected using the GraphPad software QuickCalcs
(P < 0.05). All data were expressed as mean val-
ues  SEM. Differences between MA and AD cases
were considered statistically significant at *P < 0.05,
**P < 0.01, ***P < 0.001 vs. MA; #P < 0.05,
##P < 0.01, ###P < 0.001 vs. ADI–II/0-A and
$P < 0.05 vs. ADIII–IV/0–C and ADV–VI/B–C.
Immunohistochemistry
Formalin-fixed, paraffin-embedded, de-waxed sections
4-µm thick of the frontal white matter of cases listed in
Table 1 were processed for specific immunohistochem-
istry. The sections were boiled in citrate buffer
(20 min) to retrieve protein antigenicity. Endogenous
peroxidases were blocked by incubation in 10% metha-
nol, 1% H2O2 solution (15 min) followed by 3% normal
horse serum solution. Then the sections were incubated
at 4°C overnight with one of the primary rabbit poly-
clonal antibodies: NG2 (used at a dilution of 1:200;
Sigma-Aldrich, Merck, Darmstadt, GE), Olig2 (used at a
dilution of 1:500, Sigma-Aldrich, Merck); HDAC2 (di-
luted 1:100, Abcam, Cambridge, UK); GLUT 1 (diluted
1:100, Abcam); or with one of the primary mouse
monoclonal antibodies: PLP1 (used at a dilution of
1:100, Lifespan Biosci, Seattle, WA, USA), CNPase
(used at a dilution of 1:100, Sigma-Aldrich, Merck),
MBP (diluted 1:1000, Abcam) and GFAP (diluted
Table 2. Taqman probes, gene names and identification
Gene Full name Reference




MAG Myelin-associated glycoprotein Hs01114387_m1
MAL Mal, T-cell differentiation protein Hs00360838_m1
MBP Myelin basic protein Hs00921945_m1










MYRF Myelin regulatory factor Hs00973739_m1
NG2 Neural/glial antigen 2 Hs00426981_m1







PDGFRA Platelet-derived growth factor
receptor, alpha polypeptide
Hs00998018_m1
PLP1 Proteolipid protein 1 Hs00166914_m1
SLC2A1 Solute carrier family 2 (facilitated
glucose transporter), member 1
Hs01102423_m1
SOX-10 SRY-box 10 Hs00366918_m1
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1:1000, Diagnostic BioSyst, CA, USA). Following incu-
bation with the primary antibody, the sections were
incubated with EnVision + system peroxidase (Dako,
Agilent Technologies, Santa Clara, CA, USA) for
30 min at room temperature. The peroxidase reaction
was visualized with diaminobenzidine and H2O2. Con-
trol of the immunostaining included omission of the
primary antibody; no signal was obtained following
incubation with only the secondary antibody. Sections
were slightly counterstained with haematoxylin.
Quantification of NG2-, Olig2- and HDAC2-im-
munoreactive cells in the WM was done by counting
the number of positive cells in areas of the WM located
about 1 cm below the subcortical U fibres of the frontal
lobe at the level of the head of the caudate and puta-
men chosen at random. Microphotographs were
obtained at magnifications of 9 200 or 9 400, cover-
ing areas of 0.126 mm2 and 0.038 mm2, respectively,
in three nonconsecutive sections per case using a DP25
camera adapted to an Olympus BX50 light microscope.
The number of positive cells was counted directly on
the figures and expressed as the number of positive
cells per area (0.038 mm2 for NG2- and HDAC2-im-
munoreactive cells, and 0.126 mm2 for Olig2-positive
cells). The normality of distribution of fold-change val-
ues was analysed with the Kolmogorov–Smirnov test.
Results were analysed with one-way ANOVA and post
hoc Tukey; differences were considered statistically sig-
nificant at * MA vs. AD; #: ADI–II vs. ADIII–IV or
ADV–VI; $: ADIII–IV vs. ADV–VI; significance levels
were set at: *, # P < 0.05, **, ## P < 0.01, and ***,
###, $$$ P < 0.001. No attempts were made to quan-
tify the densitometry of GLUT1.
Densitometric quantification of PLP1 immunoreactiv-
ity was acquired in the same areas as those indicated
for NG2-, Olig2- and HDAC2-immunoreactive cells fol-
lowing a similar procedure to that described for
Kl€uver–Barrera-stained sections. Photomicrographs
were obtained at a magnification of 9 200, covering
an area of 0.126 mm2, using a DP25 camera adapted
to an Olympus BX50 light microscope. The pictures,
two areas per case in every case, were analysed using
Photoshop software. The density of PLP1 was calcu-
lated as the intensity of brown colour normalized by
the total area excluding white spaces of the nuclei and
expressed as arbitrary units per area. The normality of
distribution was analysed with the Kolmogorov–Smir-
nov test. Results were analysed with one-way ANOVA
and post hoc Tukey. Differences between MA and the
three stages of pure AD cases were considered statisti-
cally significant at: * MA vs. AD; #: ADI–II vs. ADIII–
IV or ADV–VI; $: ADIII–IV vs. ADV–VI. Significance
levels were set at: *, # P < 0.05, **, ## P < 0.01 and
***, ###, $$$ P < 0.001.
Results
White matter alterations in the general series
Representative examples of the diversity of WM
changes in cases with AD pathology without and with
co-morbidities (AD-Co) are shown in Figure 1. This
illustrates the variability in WM alterations which may
concur in cases with AD pathology.
Densitometric studies of the central myelin were car-
ried out in the AD series and in MA (Figure 2A). The
density of myelin was significantly reduced in AD with-
out co-morbidities and in AD-Co when compared with
MA (P = 0.000 and P = 0.000 respectively). Myelin
density was significantly lower in AD-Co when com-
pared with AD cases without co-morbidities
(P = 0.003) (Figure 2B).
Regarding AD cases without co-morbidities, no sig-
nificant differences, but rather a tendency to reduced
myelin density was seen in AD stages V–VI when com-
pared with AD stages I–II and AD stages III–IV (Fig-
ure 2C).
RNA expression of genes related to oligodendroglia
and myelin in WM of AD without co-morbidities
Results of RT-qPCR are summarized in Figure 3. The
expression of several genes linked to the oligodendrocyte
lineage was reduced at stages III–IV/0–C when com-
pared with MA and with AD stages I–II/0-A including
OLIG1 (P = 0.007, when compared with ADI–II/A–C)
and PDGFRA (P = 0.000 when compared with MA, and
P = 0.029 when compared with ADI–II/0-A). Levels of
PDGFRA were decreased at stages V–VI/B–C when com-
pared with MA (P = 0.000); PDGFRA and OLIG1 levels
were also significantly decreased at stages V–VI/B–C
when compared with levels at stages ADI–II/0-A
(P = 0.015 and P = 0.002 respectively). Curiously,
NG2 mRNA expression was reduced only at stages
ADV–VI/B–C when compared with levels of MA and AD
stages I–II/0-C (P = 0.006 and P = 0.027 respectively).
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However, other markers of oligodendrocyte differentia-
tion such as SOX10 and NKX-2, as well as OLIG2, were
not significantly altered, although OLIG2 showed a
trend to decrease at middle stages of AD.
Regarding genes involved in myelin synthesis, MYRF
mRNA expression, the product of which triggers myeli-
nation, was significantly increased in ADI–II/0-A and
ADV–VI/B–C when compared with MA (P = 0.002 and
P = 0.033 respectively). MYRF expression was tran-
siently reduced to normal levels at stages III–IV/0–C
when compared with ADI–II/0-A and ADV–VI/B–C
(P = 0.005 and P = 0.049 respectively). In contrast,
the majority of genes which encode proteins of the mye-
lin sheet showed reduced expression levels at AD stages
III–IV/0-C when compared with MA or with AD stages
I–II/0-C: MBP (P = 0.009 when compared with MA),
PLP1 (P = 0.003 when compared with AD stages I–II/
0-A), and CNP, MAG, MAL, MOG and MOBP when
compared with MA (P = 0.006, P = 0.005, P = 0.006,
P = 0.035 and P = 0.041 respectively). Curiously, the
mRNA expression levels of several myelin-related genes
were within normal values at AD stages V–VI/B–C,
including MBP, PLP1, CNP, MAL, MOG and MOBP. Yet
levels of MAG were decreased in ADV–VI/B–C when
compared with MA (P = 0.032) (Figure 3).
The expression of the gene coding for glucose trans-
porter (SLC2A1) was reduced in ADV–VI/B–C when
compared with MA (P = 0.039). In contrast, the
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)
Figure 1. Representative formalin-fixed, paraffin-embedded, de-waxed coronal sections of the frontal cortex at the level of the head of the
caudate and putamen, stained with Kl€uver–Barrera. (A) AD stage V/C, the absence of co-morbidities (M, 82y); (B) ADIII–IV/A presenting
with a frontal infarct (M, 78y); (C) Patient categorized as mixed dementia suffering from HTA and extensive WM hyper-lucencies, AD
stage III–IV/A, LBD stage 3 (M, 75y); (D) Patient with chronic respiratory insufficiency and terminal hypoxia, AD pathology stage II/0
(M, 74y); (E) Patient with chronic respiratory failure, abnormal behaviour of nondetermined origin and AD- pathology stage III/0 (M,
54y); (F) Patient with cognitive impairment, focal WM hyper-lucencies, lacunar infarcts, HTA and AD stage V/C (M, 67y); (G) Patient
with cognitive impairment, HTA, WM hyper-lucencies and AD pathology stage II/0 (M, 40y); (H) Patient with severe cognitive
impairment, type II diabetes, hyperlipidaemia, obesity, HTA, renal failure, argyrophilic grain disease stage II and AD pathology III/A (M,
76y); (I) Patient with hepatic encephalopathy and AD pathology stage III/A (M, 58y); (J) Patient with no neurological symptoms, and
the absence of clinical and pathological co-morbidities, categorized as AD stage III/A (M, 69y); (K) Patient with mild cognitive
impairment, WM hyper-lucencies, HTA and AD pathology stage III/B (M, 72y); (L) Patient with long-lasting dementia, the absence of
risk factors of cerebral circulatory disturbance, and affected by ADVI/C, argyrophilic grain disease stage II and TDP-43 proteinopathy (M,
76). The figure makes it evident that there is variable involvement of the WM in association with distinct cerebral and systemic disorders
concomitant with AD pathology. M: man. Compare the variability of WM involvement in cases B, C, E, H, I and K categorized as AD
with co-morbidities (AD-Co) with J categorized as AD without co-morbidities, all of them stage ADIII–IV of Braak and Braak. Cases D and
G, classified as AD-Co stage II, also show decreased staining of the centrum semi-ovale when compared with stage III of AD without co-
morbidities (J). Differences are also observed between AD without co-morbidities stage V (A) in comparison with AD-Co stages V and VI
(F and L). Note that all cases in the figure correspond to males to avoid gender bias).
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expression levels of MCT1, the gene coding for solute
carrier family 16 (monocarboxylic acid transporter,
member 1), were not significantly altered, but did show
a trend to reduction at advanced stages of AD (Fig-
ure 3).
Immunohistochemistry
NG2 (which identifies oligodendroglial precursor cells)
immunoreactivity in the WM was detected as small
granules in the cytoplasm of a subpopulation of glial
cells, whereas Olig2 (which is expressed in oligodendro-
cytes) immunoreactivity decorated the nucleus of oligo-
dendrocytes. The number of NG2-positive cells
decreased with disease progression, but significant dif-
ferences were detected only between ADI–II/0-A when
compared with ADIII–IV/0-C (P = 0.001), and between
ADI–II/0-A compared with ADV–VI/B–C (P = 0.000).
Olig2-positive cells also decreased with disease progres-
sion: MA vs. ADIII–IV/0–C (P = 0.011), MA vs. ADV–
VI/B–C (P = 0.000), ADI–II/0-A vs. ADIII–IV/0–C
(P = 0.016), ADI–II/0-A vs. ADV–VI/B–C (P = 0.000)
and ADIII–IV/0–C vs. ADV–VI/B–C (P = 0.000). More-
over, Olig2-immunoreactive cells with large, dense and
often elongated nuclei were found in ADV–VI/B–C (Fig-
ure 4, Figure 6).
HDAC2 immunoreactivity was found in the nucleus
of glial cells. The number of HDAC2-positive cells and
(A) (B) (C)
Figure 2. Densitometric values of myelin sheet phospholipids as revealed in Kl€uver–Barrera-stained sections of the centrum semi-ovale at
the level of the head of the caudate and putamen in MA, AD with co-morbidities (AD-Co), and cases of AD without co-morbidities (AD).
Values are expressed as arbitrary units per area. (A) The area of densitometric studies is indicated by the circle; Kl€uver–Barrera staining
in an MA case. Note that the area is separated from the periventricular white matter and the subcortical U-fibres. (B) Significant decrease
in AD without co-morbidities (n = 33) and AD-Co (n = 173) is seen when compared with MA (n = 20). The intensity of myelin staining
is significantly lower in AD-Co when compared with AD cases. (C) No significant differences, but a tendency to reduced myelin intensity
is seen in AD without co-morbidities at stages V–VI/B–C (ADV–VI) when compared with AD at stages I–II/0-A (ADI–II) and AD at stages
III–IV/0-C (ADIII–IV). ADI–II/0-A, n = 9; ADIII–IV/0–C, n = 8; ADV–VI/B–C, n = 16. One-way ANOVA and post hoc Tukey, ***P < 0.001
AD and AD-Co compared with MA; ##P < 0.001: AD-Co compared with AD without co-morbidities.
Figure 3. mRNA expression of selected oligodendrocyte- and myelin-related genes in the frontal white matter of MA, AD without co-
morbidities stages I–II/0-A (ADI–II), III–IV/0-C (III–VI) and V–VI (B, C). Abbreviations may be seen in Table 2. One-way analysis of
variance (ANOVA) followed by Tukey posttest or Kruskal–Wallis test followed by Dunn’s post hoc test when required using the SPSS
software; *P < 0.05, **P < 0.01, ***P < 0.001 vs. MA; #P < 0.05, ##P < 0.01 vs. ADI–II; $P < 0.05 vs. ADIII–IV and ADV–VI (see
Methods for statistical studies).
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the intensity of the staining in the remaining cells sig-
nificantly decreased with disease progression: MA vs.
ADIII–IV/0–C (P = 0.007), MA vs. ADV–VI/B–C
(P = 0.000), ADI–II/0-A vs. ADIII–IV/0-C (P = 0.035);
ADI–II/0-A vs. ADV–VI/B–C (P = 0.000), and ADIII–
IV/0-C vs. ADV–VI/B–C (P = 0.000) (Figures 4 and 6).
GLUT1 (glucose transporter member 1) immunoreac-
tivity, which decorated the neuropil and the wall of the
small blood vessels, decreased in AD with disease pro-
gression. However, no attempt was made to quantify
the density of the immunostaining due to individual
variations (Figure 4).
Regarding myelin proteins, the intensity of PLP1,
CNPase and MBP immunoreactivity decreased with dis-
ease progression (Figure 5). Densitometric studies were
carried out only for PLP1. Significant reduction was
observed in ADI–II/0-A, ADIII–IV/0–C and ADV–VI/B–
C when compared with MA (P = 0.000, P = 0.000
and P = 0.002 respectively). Moreover, significant dif-
ferences were also seen between ADI–II/0- vs. ADIII–
IV/0-C (P = 0.000) and ADIII–IV/0-C vs. ADV–VI/B–C
(P = 0.000) (Figure 6).
In contrast, GFAP immunoreactivity showed an
increase in the number and intensity in individual
astrocytes in the WM in parallel sections (data not
shown), in agreement with previous data from several
authors, as reviewed elsewhere [78].
Discussion
This study was designed to learn about WM abnormali-
ties in cases with AD pathology without co-morbidities
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)
(M) (N) (O) (P)
Figure 4. Immunohistochemistry to cellular markers NG2, Olig2, HDAC2 and SLC2A1:GLUT1 in MA individuals (A, E, I, M), and in
cases with AD without co-morbidities at stages ADI–II/0-A (ADI–II) (B, F, J, N), ADIII–IV/0–C (ADIII–IV) (C, G, K, O) and ADV–VI/B–C
(ADV–VI) (D, H, L, P). Decreased numbers of NG2-, Olig2- and HDAC2-immunoreactive cells are observed at middle, and particularly,
advanced stages of AD. Large hyperchromatic Olig2-positive cells are also observed in ADV–VI. GLUT1 immunoreactivity is manifested as
a fine uniform meshwork in the neuropil which is progressively disrupted into patches of variable immunoreactivity with disease
progression. Paraffin sections, slightly counterstained with haematoxylin; NG2, HDAC2, bar = 50 µm; Olig2 and SLC2A1, bar = 45 µm.
Insert in MA NG2 is at greater magnification to show small positive granules characteristic of NG2 immunoreactivity. Insert in Olig2
ADV–VI shows a representative large hyperchromatic Olig2-immunoreactive cell; these cells are commonly present in ADV–VI.
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at different stages of disease progression. For this pur-
pose, our first approach was to consider all cases in
which one of the post mortem neuropathological
diagnoses was AD pathology in a continuous series of
necropsy cases in a general hospital. Following this
procedure, 206 of the 470 cases with adequate clinical
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)
Figure 5. Immunohistochemistry to myelin markers PLP1, CNPase and MBP in the centrum semi-ovale of the frontal lobe in MA (A, E,
I), and in cases with AD without co-morbidities at stages ADI–II/0-A (ADI–II) (B, F, J), ADIII–IV/0-C (ADIII–IV) (C, G, K) and ADV–VI/B–
C (ADV–VI) (D, H, L). Representative images show reduced immunoreactivity with disease progression, and small PLP1- and CNPase-
immunoreactive dots in ADV–VI. Paraffin sections, slightly counterstained with haematoxylin; bar = 50 µm.
Figure 6. Quantitative study of NG2-, Olig2- and HDAC2-immunoreactive cells in the frontal WM per area of AD cases without co-
morbidities (0.038 mm2 for NG2- and HDAC2-immunoreactive cells, and 0.126 mm2 for Olig2-positive cells; see Methods). The number
of positive cells decreases with increasing stages of AD pathology. MA, n = 10; ADI–II/0-A, n = 9; ADIII–IV/0-C, n = 8; ADV–VI/B–C,
n = 16. One-way ANOVA and post hoc Tukey; *: MA vs. ADIII–IV/0-C (ADIII–IV) or ADV-VI/B–C (ADV–VI); #: ADI–II/0-A (ADI–II) vs.
ADIII–IV or ADV–VI; $: ADIII–IV vs. ADV–VI; significance level set at *, # P < 0.05, ** P < 0.01 and ***, ###, $$$ P < 0.001.
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information and histological quality to carry out densit-
ometric studies of the WM of the frontal lobe were
selected. Interestingly, 89% of cases aged 65 and older
had AD pathology, a slightly higher figure than the
percentage already reported for this age group [79,80].
Review of the clinical history and neuropathological
study revealed that 84% had concomitant cerebrovas-
cular pathology; clinical morbidities such as HTA, type
II diabetes, hyperlipaemia, renal or liver failure and
chronic respiratory failure; cerebrovascular pathology;
age-related neurodegenerative diseases, such as other
tauopathies, Lewy body pathology and TDP-43 pro-
teinopathy; and long agonic state, or vegetative state,
which were putative causes of WM alterations. After
further selection, 33 were categorized as AD cases
without co-morbidities.
It can be argued that not all AD cases had cognitive
impairment and dementia, and therefore, they cannot be
classified as AD. Moreover, six cases of AD stages I–III
without co-morbidities did not have b-amyloid deposits,
and they might be classified as Primary age-related
tauopathy (PART) [81]. However, PART has also been
considered as part of AD [82]. We have followed here
this consideration because AD and PART share the same
NFT pathology at early stages of the disease.
Densitometric analysis performed on Kl€uver–Barrera-
processed sections of the central WM of the frontal lobe
at the level of the head of caudate and putamen
revealed significant differences between MA individuals
and cases with AD. It is important to stress that the
MA group was composed of individuals with an age of
about 25 years younger than that of the AD groups.
Therefore, MA must be not considered an age-matched
control group, but rather a representation of the mye-
lin in normal MA individuals. A significant reduction
in phospholipid myelin in elderly, as revealed with
Kl€uver–Barrera staining, is consistent with the idea
that myelin in the cerebral WM decreases with age, as
already noted in the Introduction. Since the majority of
individuals aged 65 and older had AD pathology, it is
difficult to ascertain whether changes in the AD groups
were linked to ageing or associated with AD pathology.
More practical is the observation that myelin decay
is greater in AD cases with co-morbidities (AD-Co) than
in AD cases with no co-morbidities. The age of the indi-
viduals has been assessed in every case, and the mean
values  SEM have been obtained for every stage both
in the total series and in pure AD. Values are similar in
both groups, and then comparisons are not biased by
differences in the age, but in the presence or absence of
co-morbidities. Since the majority of cases with AD in
our series had co-morbidities, it may be inferred that
part of the WM lesions commonly reported in the
elderly and in AD during life cannot be ascribed solely
to age and AD, but rather to common concomitant risk
factors and pathologies affecting the ageing brain.
Biochemical alterations in WM in AD without co-
morbidities
Previous studies have shown alterations in the lipid
composition of the WM in AD. Galactosylceramide (Gal-
Cer) and sulphatides, synthesized by oligodendroglia in
the CNS, are major components of myelin. Reduced Gal-
Cer and sulphatide levels, increased cholesterol and
increased fatty acid contents occur in cortical grey and
WM in AD [83-88]. Levels of GalCer and sulphatide
slightly decreased in the frontal and temporal cortex,
and in WM matter at stages III–IV, and more markedly
at stages V–VI in AD [89]. Curiously, the activity of cera-
mide synthase 2, which catalyses the synthesis of very
long chain ceramides, decreased in brain temporal cor-
tex at stages I–II and frontal cortex at stages III–IV pre-
ceding neurofibrillary tangle formation, suggesting that
alterations of ceramide synthesis occur earlier than pre-
viously suspected in the spread of AD [89]. Our observa-
tions on Kl€uver–Barrera-stained sections are in line with
biochemical studies showing decreased levels of phos-
pholipid components of myelin in AD when compared
with MA individuals. Differences are not as clear among
stages in AD cases without co-morbidities, although a
trend to reduction is observed at advanced stages.
Regarding myelin proteins, progressive reduction in
the levels of myelin basic protein (MBP), myelin prote-
olipid protein (PLP) and 20,30-cyclic nucleotide 30-phos-
phodiesterase (CNP) has been reported in the WM of
the parietal and occipital lobes in AD correlating with
Braak stages V–VI [90]. Reduced levels of CNP have
also been recorded in the WM of the frontal lobes in
advanced AD [89,90].
Our observations are restricted to cases with AD
pathology without co-morbidities. mRNA expression
levels of MBP, PLP1, CNP, MAG, MAL, MOG and
MOBP were preserved in the frontal white matter at
stages I–II/0-A when compared with MA, but they
were transiently decreased at stages III–IV/0-C, and
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increased thereafter to reach nearly MA levels at stages
V–VI/B–C. Regarding protein expression, densitometric
studies of PLP1 in the same region revealed a signifi-
cant decrease in PLP1 immunoreactivity at early stages
of AD, which became more marked at middle stages,
followed by a slight increase without reaching MA val-
ues at advanced stages of AD.
It is worth to stress that differences between AD
stages are not related to the age or gender of the indi-
viduals, but rather to the stage of the disease. Differ-
ences between myelin lipids, as revealed with Kl€uver–
Barrera staining, and myelin proteins as shown by RT-
qPCR and immunohistochemistry, in the same cases
may be related to differing preciseness of the methods
employed. However, the relative recovery of myelin
proteins, but not of phospholipids, at advanced stages
of the disease deserves further study, including analysis
of a possible structural imbalance between lipid and
protein components of the myelin sheet in the elderly
and in AD. Studies in the aged human post mortem
brain have shown decreased internodal distance,
reduced axon thickness and greater vulnerability of
thin myelinated fibres compared with large myelinated
fibres [7]. Little is known about this aspect in AD.
b-amyloid and tau
It has been suggested that cortical atrophy with neuron
loss is not the main cause of WM damage in AD, as
revealed by pioneering neuropathological studies [29],
and later supported by combined MRI and post mortem
examination [9,91]. However, this hypothesis has been
brought into question by other studies. The impact of
b-amyloid on oligodendrocytes is equivocal. On the one
hand, b-amyloid is toxic to oligodendrocytes as identi-
fied in in vitro models, transgenic mice and familial AD
[92-96]. However, Ab oligomers also promote oligoden-
drocyte differentiation and maturation in isolated oligo-
dendrocytes and in organotypic cerebellar slices [97].
In fact, deterioration of the WM parallels, but does not
correlate with either the total amount or the regional
localization of b-amyloid plaques [98]. However, sol-
uble b-amyloid is abundant in the WM in the absence
of plaques in AD [99]. Therefore, the possibility of
oligodendrocyte damage by soluble b-amyloid in AD
cannot be ignored.
WM damage has been correlated with tau pathology
in the cerebral cortex [10,101]. Therefore, myelin
breakdown in AD has been posited as being linked to
axonopathy and transport deficits [10-102]. In favour
of WM axonopathy resulting from tau pathology is the
presence of WM breakdown in transgenic mice bearing
the P301L mutation in the mapt gene [13]. Yet, WM
disruption does not correlate exactly with the localiza-
tion and distribution of NFTs in AD [29]. The present
findings further support the concept of early alteration
of the WM in AD, as transcription of oligodendrocyte
and myelin genes in the frontal WM is altered at stages
III–IV/0–C at which point no NFTs or neuron loss are
found in this region.
Oligodendrocytes and NG2-glia
Previous studies have shown reduced size of the nuclei
of oligodendrocytes [14], and decreased numbers of
Olig2- and NG2-glia-immunoreactive cells [15,106].
Moreover, several oligodendroglial nuclei in the WM
show oxidative damage (8-OHdG immunoreactivity),
whereas other oligodendrocytes exhibit increased
expression of p53 as a marker of stress, and a senes-
cent phenotype (SA-b-gal immunoreactive) [17,108].
Reduction in the expression of NG2 and PDGFRA
mRNA (stages V–VI/A–C, and stages III–IV/0–C and
V–VI/A–C respectively), together with reduced numbers
of NG2- and Olig2-immunoreactive cells in the WM,
points to progressive decline of the oligodendrocyte lin-
eage in the frontal WM with disease progression, which
is in line with the demonstration of early alterations of
the oligodendrocyte lineage linked to AD pathology
[15,106].
Reduction in NG2-glia is important as it probably
compromises the regenerative ability of the WM to
restore the number of oligodendrocytes and myelin
homeostasis. Reduced numbers of oligodendrocytes and
altered control of glucose and lactate metabolites neces-
sary for trophic support for axons may produce, in
turn, altered axonal function, and axonal degeneration.
This scenario takes place at a limited rate in the ageing
human brain [19], but its potentially damaging effect is
overwhelmed in AD [110].
Histone deacetylases (HDACs) remove specific acetyl
groups on a histone enabling it to interact with DNA
thereby modulating gene transcription. Increased
HDAC2 facilitates oligodendrocyte differentiation
[73,74]. Thus, HDAC2 reduction likely compromises
oligodendrogenesis.
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An intriguing feature in this scenario is the increased
expression of MYRF mRNA at early and late stages of
AD. Regarding the number of oligodendrocytes,
reduced expression of MYRF mRNA could be expected,
whereas with MYRF being a factor regulating the
expression of several myelin genes, the expression of
such genes would be expected to increase in AD. We
have no explanation for the altered MYRF regulation
and response in AD.
Transgenic mice expressing b-amyloid and tau as
animal models to uncover WM abnormalities in AD
WM alterations have also been examined in several
types of transgenic mice carrying the APP/PS1
(K670N/M671L Swedish and PS1dE9) mutation, PS1
mutation, and 5xFAD mutation (Swedish mutation,
1716V Florida mutation, V717I London mutation, and
PS1 with M146L and L286V mutation), as well as
3xTg-AD mice (APP Swedish mutation, a presenilin
knock-in mutation and P301L tau) [111-117].
In all these models, WM alterations characterized by
myelin loss and decreased numbers of oligodendrocytes
occur at early stages before the appearance of b-amy-
loid plaques, and they increase for a limited period of
disease progression. Oligodendroglial cell death and
myelin loss occur at early stages in 3xTg-AD mice
[112,113], and region-specific alterations appear before
b-amyloid and tau pathology [112]. However, murine
models of b-amyloid deposition show reparative
responses at later stages of the disease [15,114-116].
No similar increase in Olig2 and NG2-immunoreactive
cells occurs in AD, as shown in the present work and
in previous studies [15-106,109,110]. However, a cer-
tain normalization of the mRNA expression of several
myelin-related genes here observed in AD without co-
morbidities has its counterpart in transgenic models.
As a working hypothesis, it may be suggested that
repair of oligodendrocyte lineage is activated in AD and
transgenic models, but regeneration is minimized in AD
when compared with transgenic murine models.
Vascular alterations in ageing and AD
Vascular and circulatory alterations including
atherosclerosis, small blood vessel disease, tortuous and
coiled arterioles, reduced vascular density and cerebral
complications such as micro-infarcts, hypoperfusion
and micro-bleeds are common in aged human brains
[4,118-123].
In addition to vascular alterations linked to age,
which may occur in any patient, hypoperfusion linked
to b-amyloid deposition, alteration of the blood vessel
walls, increased RAGE, altered microglia and astrocytes
with senescent forms are constant in AD. b-amyloid
angiopathy is found in the vast majority of cases
[124,125] and it shows an early predilection for corti-
cal blood vessels. b-amyloid deposition is accompanied
by decreased expression of efflux receptor for b-amyloid
and increased influx receptor RAGE in AD [126,127].
Other alterations include atrophy, oedema and
increased numbers of pinocytic vesicles in endothelial
cells; thickening and focal disruption of the basal mem-
brane; increase in heparan sulphate, proteoglycans, col-
lagen IV and laminin in the basal membrane, with
atrophy of smooth muscle fibres and augmented aqua-
porin expression in perivascular astrocytes [128-132].
These changes, in conjunction with mounting evidence
of altered blood–brain barrier in AD [133-136], lend
support to the old proposal of reduced perfusion of the
brain as a pathogenic factor in AD [137-139].
Our study in AD cases without co-morbidities
excludes major vascular pathology and systemic circu-
latory factors which could have an impact on the
integrity of oligodendrocytes and myelin. However, we
cannot rule out a role for primary alterations in blood
vessels linked to AD since specific vascular pathology is
one of the manifestations of AD.
Conclusions
WM alterations in AD have been considered the result
of cerebrovascular dysfunction [138,139], axonopathy
linked to retrograde neuronal tau deposition [10-102],
or homeostatic responses to age-related myelin break-
down [140]. These factors are not mutually exclusive,
but rather reinforce each other with age and disease
progression. This study has tried to minimize co-mor-
bidities in a general population with AD pathology
dying in a general hospital. It may be argued that: i.
the population dying in a general hospital is not repre-
sentative of the total population whose health status is
better than that represented by in-patients, and that
co-morbidities are less frequent and serious in the gen-
eral population when compared with individuals dying
in the hospital; and ii. vascular ageing, and of course
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vascular changes linked to AD, cannot be ruled out in
the pathogenesis of WM disorders in the present series
of AD cases without co-morbidities. These are undoubt-
edly reasonable objections.
Yet, several studies have stressed the role of oligo-
dendrocytes as important players in the pathogenesis of
distinct neurodegenerative diseases including AD [141-
144]. In this line, the present observations point to
early alterations of oligodendrocytes and transcription
of genes linked to myelin proteins in WM in cases with
AD pathology without co-morbidities before the appear-
ance of NFTs in these regions, and before the appear-
ance of clinical symptoms of cognitive impairment.
This suggests that oligodendrocytes are along with neu-
rons, targets of AD, and that oligodendrocytopathy is
therefore part of AD.
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